Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma. It is defined by quickly growing tumors in the lymph nodes, spleen, bone marrow, liver, and other tissues and organs. It can occur at any age but is most common in older adults. Symptoms usually include swollen lymph nodes, fever, night sweats, fatigue, and weight loss.
Dr. Elif Yilmaz from the Harold C. Simmons Cancer Center offers a positive view of this disease.
“DLBCL is, in fact, one of the most curable malignancies. About 60-70% of patients (in all stages) can be cured from DLBCL.”
Even though this disease is aggressive and spreads quickly, this form of cancer can often go into complete remission and also be cured. Dr. Praveen Ramakrishnan from UT Southwestern Medical Center teaches us that two-thirds of patients can be cured with upfront treatment. For those patients who are refractory or relapsed, there are three types of second-line therapies available:
Dr. Leandro Cerchietti from Weill Cornell Medical Center describes the most common form of treatment for DLBCL: the R-CHOP regimen. This is a combination of immunotherapy and chemotherapy, and response rates are very high. Approximately 30% of patients will not be cured by this combination therapy and will require additional treatment.
R-CHOP is a combination known as chemoimmunotherapy. It is made up of the following medications:
R-CHOP is typically administered intravenously (through a vein) in cycles, with each cycle lasting several weeks. The exact length and number of cycles depend on the specific patient and their lymphoma characteristics.
R-CHOP can cause various side effects, including fatigue, nausea, vomiting, hair loss, mouth sores, and an increased risk of infection. These side effects can vary depending on the individual and the dosage received.
It is difficult for doctors to determine the length of time for durable remission or cure. It can depend on many factors:
The longer your remission lasts, the lower your chances of relapse. A relapse is most likely to occur within two years after treatment.
Continue learning about DLBCL with HealthTree. See below some of the most popular resources:
Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma. It is defined by quickly growing tumors in the lymph nodes, spleen, bone marrow, liver, and other tissues and organs. It can occur at any age but is most common in older adults. Symptoms usually include swollen lymph nodes, fever, night sweats, fatigue, and weight loss.
Dr. Elif Yilmaz from the Harold C. Simmons Cancer Center offers a positive view of this disease.
“DLBCL is, in fact, one of the most curable malignancies. About 60-70% of patients (in all stages) can be cured from DLBCL.”
Even though this disease is aggressive and spreads quickly, this form of cancer can often go into complete remission and also be cured. Dr. Praveen Ramakrishnan from UT Southwestern Medical Center teaches us that two-thirds of patients can be cured with upfront treatment. For those patients who are refractory or relapsed, there are three types of second-line therapies available:
Dr. Leandro Cerchietti from Weill Cornell Medical Center describes the most common form of treatment for DLBCL: the R-CHOP regimen. This is a combination of immunotherapy and chemotherapy, and response rates are very high. Approximately 30% of patients will not be cured by this combination therapy and will require additional treatment.
R-CHOP is a combination known as chemoimmunotherapy. It is made up of the following medications:
R-CHOP is typically administered intravenously (through a vein) in cycles, with each cycle lasting several weeks. The exact length and number of cycles depend on the specific patient and their lymphoma characteristics.
R-CHOP can cause various side effects, including fatigue, nausea, vomiting, hair loss, mouth sores, and an increased risk of infection. These side effects can vary depending on the individual and the dosage received.
It is difficult for doctors to determine the length of time for durable remission or cure. It can depend on many factors:
The longer your remission lasts, the lower your chances of relapse. A relapse is most likely to occur within two years after treatment.
Continue learning about DLBCL with HealthTree. See below some of the most popular resources:
about the author
Lisa Foster
Lisa Foster is a mom of 3 daughters, a puzzle lover, a writer, and a HealthTree advocate. She believes in the mission of the foundation and the team that builds it forward. She calls Houston, Texas home.
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.